» Articles » PMID: 28573046

A Comparative Study: The Use of Collagen Implant Versus Mitomycin-C in Combined Trabeculotomy and Trabeculectomy for Treatment of Primary Congenital Glaucoma

Overview
Journal J Ophthalmol
Publisher Wiley
Specialty Ophthalmology
Date 2017 Jun 3
PMID 28573046
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To compare Ologen implant versus mitomycin-C (MMC) in combined trabeculotomy and trabeculectomy as a treatment of primary congenital glaucoma.

Setting: Sohag University Hospital, Egypt.

Design: A prospective comparative study.

Methods: Thirty-four eyes of twenty-one patients with primary congenital glaucoma were included in this study. All patients were subjected to preoperative evaluation including complete anterior segment examination under general anesthesia. The patients were divided into two groups: patients of the first group (group A) underwent combined trabeculotomy and trabeculectomy with Ologen implantation while those of the second group (group B) underwent combined trabeculotomy and trabeculectomy with MMC application.

Results: Postoperatively, the IOP in group A was as follows: 8 eyes developed IOP levels less than 14 mmHg (complete success), 3 eyes had levels between 14 and 16 mmHg (accepted result), 2 eyes had levels between 16 and 20 mmHg (guarded result), and only 2 eyes showed levels exceeding 20 mmHg (failed procedure), while in group B, 7 eyes showed complete success, 3 eyes had accepted result, 3 eyes had guarded result, and 2 eyes had failed procedure.

Conclusion: Ologen is a safe and effective adjuvant in combined trabeculotomy and trabeculectomy for treatment of primary congenital glaucoma.

Citing Articles

Subscleral trabeculectomy with Ologen implant versus mitomycin C in primary infantile glaucoma.

Kassem R, Esmael A Saudi J Ophthalmol. 2025; 38(4):352-359.

PMID: 39943960 PMC: 11811400. DOI: 10.4103/sjopt.sjopt_204_23.


Comparison between modified and conventional combined Trabeculotomy-Trabeculectomy with Mitomycin-C for intraocular pressure reduction in primary congenital glaucoma.

Raza A, Chaudhary M, Mushtaq A, Khan A Pak J Med Sci. 2024; 40(9):1937-1940.

PMID: 39416626 PMC: 11476172. DOI: 10.12669/pjms.40.9.8788.


Combined trabeculotomy-trabeculectomy with and without augmentation in primary congenital glaucoma: triple-armed randomized controlled trial.

Khairy M, Kenawy S, Fawzi K, Al-Nashar H Int Ophthalmol. 2022; 43(5):1591-1600.

PMID: 36266601 DOI: 10.1007/s10792-022-02558-1.


Ologen augmentation of Ahmed glaucoma drainage devices in pediatric glaucomas.

Jacobson A, Rojas C, Bohnsack B BMC Ophthalmol. 2021; 21(1):72.

PMID: 33546636 PMC: 7863366. DOI: 10.1186/s12886-021-01827-4.


Surgical interventions for primary congenital glaucoma.

Gagrani M, Garg I, Ghate D Cochrane Database Syst Rev. 2020; 8:CD008213.

PMID: 32816311 PMC: 8094178. DOI: 10.1002/14651858.CD008213.pub3.


References
1.
Chen H, Ritch R, Krupin T, Hsu W . Control of filtering bleb structure through tissue bioengineering: An animal model. Invest Ophthalmol Vis Sci. 2006; 47(12):5310-4. DOI: 10.1167/iovs.06-0378. View

2.
Cheng J, Cai J, Li Y, Wei R . Intraoperative mitomycin C for nonpenetrating glaucoma surgery: a systematic review and meta-analysis. J Glaucoma. 2010; 20(5):322-6. DOI: 10.1097/IJG.0b013e3181e3d2f7. View

3.
Shaarawy T, Nguyen C, Schnyder C, Mermoud A . Comparative study between deep sclerectomy with and without collagen implant: long term follow up. Br J Ophthalmol. 2003; 88(1):95-8. PMC: 1771937. DOI: 10.1136/bjo.88.1.95. View

4.
Seibold L, Sherwood M, Kahook M . Wound modulation after filtration surgery. Surv Ophthalmol. 2012; 57(6):530-50. DOI: 10.1016/j.survophthal.2012.01.008. View

5.
Hsu W, Ritch R, Krupin T, Chen H . Tissue bioengineering for surgical bleb defects: an animal study. Graefes Arch Clin Exp Ophthalmol. 2008; 246(5):709-17. DOI: 10.1007/s00417-007-0744-9. View